Captor TherapeuticsS.A.Active
Research and experimental development in natural sciences and engineering
KRS: 0000756383 NIP: 8943071259 REGON: 36338176500000
Overview
Registry date
2018-11-07
Share capital
$171,620.66
Activity description
Captor Therapeutics is a biotech company that utilizes Targeted Protein Degradation (TPD) technology to discover and develop therapies for diseases with unmet medical needs, such as cancer and autoimmune disorders. The company operates from Basel, Switzerland, and Wrocław, Poland, and employs advanced techniques like CRISPR/Cas9 for genome editing and its Optigrade™ platform for drug candidate discovery. Their integrated expertise in protein engineering, structural biology, and molecular modeling enables them to optimize lead compounds effectively.
Registered address
Ul. Duńska 11, 54-427 Wrocław, Poland
Website
captortherapeutics.plWebsite active
Electronic delivery address
AE:PL-88161-66597-WVWGS-21
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-01-01.Active
Authorized Representatives
Ownership
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| MikroelS.A. | $7,850,249.12 | mikroel.tech | |
| Centrum Techniki OkrętowejS.A. | $7,668,943.94 | cto.gda.pl | |
| BiokineticaS.A. | $2,726,207.44 | biokinetica.com | |
| IntodnaS.A. | $1,629,637.22 | intodna.com | |
| ProgresjaS.A. | $1,461,322.62 | progresja.co | |
| BioceltixS.A. | $1,060,222.87 | bioceltix.com/ | |
| Real ResearchS.A. | $565,296.66 | real-research.com/ | |
| Oasis DiagnosticsS.A. | $282,613.94 | oasis-diagnostics.com | |
| PolbionicaS.A. | $225,022.81 | polbionica.com/ | |
| NanosanguisS.A. | $133,800.85 | nanosanguis.com |
Change history
| Event | Details | Date | |
|---|---|---|---|
| Share capital change | 555339.70 PLN → 635339.70 PLN | 2026-06-25 |
FAQ
Last updated: 2026-06-28